How important is tafamidis to Pfizer financially?
The Vyndaqel family generated $6.38 billion in 2025 — roughly 10% of Pfizer's total revenue — making every additional year of exclusivity worth billions of dollars.
Very. Pfizer's full-year 2025 results show the Vyndaqel family (tafamidis) generated $6.38 billion worldwide, up 17% from $5.45 billion in 2024, against total company revenue of $62.6 billion. That makes tafamidis worth roughly 10% of Pfizer's annual revenue.
That scale explains the intensity of the fight over pricing, exclusivity and marketing: with generic entry now pushed to 2031, each additional year is worth billions of dollars to Pfizer. Researchers projected that tafamidis would earn approximately $23.7 billion from launch through 2029 - the earliest year it could theoretically be subject to Medicare negotiation if the orphan-drug exemption were removed.